+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Activin Receptor Type 1 - Pipeline Review, H1 2020

  • ID: 5007674
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 70 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Incyte Corp
  • Keros Therapeutics Inc
  • M4K Pharma Inc
  • Oncodesign SA
  • Sierra Oncology Inc
  • MORE
Activin Receptor Type 1 - Pipeline Review, H1 2020

Summary

According to the recently published report 'Activin Receptor Type 1 - Pipeline Review, H1 2020'; Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Activin A receptor type I (ACVR1) is a protein is encoded by the ACVR1 gene. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. It acts as a receptor for activin. It is involved for left-right pattern formation during embryogenesis.

The report 'Activin Receptor Type 1 - Pipeline Review, H1 2020' outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Oncology, Hematological Disorders and Toxicology which include indications Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Myelofibrosis, Anemia of Chronic Disease, Chemotherapy Induced Anemia, Pediatric Diffuse Intrinsic Pontine Glioma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Solid Tumor and Thrombocythemia Myelofibrosis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)
  • The report reviews Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Incyte Corp
  • Keros Therapeutics Inc
  • M4K Pharma Inc
  • Oncodesign SA
  • Sierra Oncology Inc
  • MORE
  • Introduction
  • Report Coverage
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Overview
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
  • BioCryst Pharmaceuticals Inc
  • Clementia Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Incyte Corp
  • Keros Therapeutics Inc
  • La Jolla Pharmaceutical Company
  • M4K Pharma Inc
  • Oncodesign SA
  • Sierra Oncology Inc
  • Tolero Pharmaceuticals Inc
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Drug Profiles
  • BCX-9250 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BCX-9499 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLU-782 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dipyridamole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DS-6016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INCB-00928 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KER-047 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • momelotinib dihydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TP-0184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Dormant Products
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Discontinued Products
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 07, 2019: Sierra Oncology reports decreased transfusion requirements for patients treated with Momelotinib directly compared to Ruxolitinib at ASH annual meeting
  • Dec 02, 2019: Sierra Oncology announces investor event to discuss Momelotinib data being reported at ASH
  • Nov 21, 2019: Sierra Oncology initiates study of momelotinib in myelofibrosis
  • Nov 06, 2019: Sierra Oncology to report new analyses supporting Momelotinib's anemia benefits at ASH 2019
  • Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva
  • Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)
  • Jun 27, 2019: Sierra Oncology launches campaign exploring non-dilutive strategic options to support development of its DDR Assets
  • Jun 07, 2019: FDA grants fast-track designation to bone marrow cancer drug
  • Jun 04, 2019: Sierra announces FDA regulatory clarity for Momelotinib & design of the MOMENTUM phase 3 clinical trial
  • May 28, 2019: Sierra Oncology to Present Momelotinib Overview at the Jefferies Global Healthcare Conference in New York
  • Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
  • Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019
  • Dec 03, 2018: Sierra Oncology reports robust transfusion independence rates in transfusion dependent myelofibrosis patients treated with momelotinib
  • Nov 27, 2018: Sierra Oncology to host analyst call highlighting clinical data on Momelotinib's anemia benefit
  • Nov 01, 2018: Sierra Oncology to report clinical data at ASH 2018 from translational biology study of Momelotinib in transfusion dependent patients
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by BioCryst Pharmaceuticals Inc, H1 2020
  • Pipeline by Clementia Pharmaceuticals Inc, H1 2020
  • Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Pipeline by Incyte Corp, H1 2020
  • Pipeline by Keros Therapeutics Inc, H1 2020
  • Pipeline by La Jolla Pharmaceutical Company, H1 2020
  • Pipeline by M4K Pharma Inc, H1 2020
  • Pipeline by Oncodesign SA, H1 2020
  • Pipeline by Sierra Oncology Inc, H1 2020
  • Pipeline by Tolero Pharmaceuticals Inc, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • BioCryst Pharmaceuticals Inc
  • Clementia Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Incyte Corp
  • Keros Therapeutics Inc
  • La Jolla Pharmaceutical Company
  • M4K Pharma Inc
  • Oncodesign SA
  • Sierra Oncology Inc
  • Tolero Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll